Abstract: Method of, and dosage unit for, inhibiting angiogenesis in an aminal having an intestinal wall by administering to the animal, orally or anally, an effective amount of shark cartilage, particularly finely divided shark cartilage in solid dosage form such as a tablet, capsule, suppository, for passing through the intestinal wall of the animal as a suspension.

Abstract: Systemic antiviral treatment using a narrow class of aliphatic straight-chain saturated monohydric alcohols which have from 27 to 32 carbons in the chain in physiologically compatible compositions for injection or trans-mucus membrance introduction into humans and other mammals is disclosed.

Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta. molecules in which from about 1 to 10 amino acid residues have been deleted, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Le u, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.

Abstract: Solid delivery systems which at body temperature exhibit controlled release and bioadherence characteristics. These systems are emulsions which are water in oil in nature and whose internal phase is greater than that of the external phase. That is, the internal phase comprises at least 60% of the system.

Abstract: Method of treatment of immunodeficiency disease which comprises administering therapeutically effective amount of sex hormone to a subject in need of such treatment.

Abstract: A food composition containing a fat and an anti-oxidant is disclosed. The anti-oxidant is prepared by the extraction of natural anti-oxidants from plant substances.

Abstract: Medicinal compositions containing a water soluble absorption promoter having chelating activity, preferably in the presence of a salt at a concentration exhibiting higher osmotic pressure than isotonic sodium chloride solution, to promote absorption of the medicine through a gastrointestinal organ such as colon or rectum, and through the vagina.

Abstract: Nifedipine is formulated into a reactally administrable composition for administration to humans and animals to effect coronary dilation and for hypotensive effect.

Abstract: A preparation containing an absorption promoter selected from N-acyl amino acid derivatives or N-acyl peptide derivatives represented by the formula: R-CO-A (R is an aliphatic hydrocarbon group, an aromatic hydrocarbon group or an aryl-substituted lower hydrocarbon group which may optionally be substituted, and A is an amino acid residue or a peptide residue), preferably in the presence of a salt at a concentation exhibiting higher osmotic pressure than isotonic sodium chloride solution, and a medicine is found to promote absorption of the medicine through a gastrointestinal organ such as the colon and rectum, and through the vagina.

Abstract: A composition for suppository bases consisting of a water-insoluble fat and an adduct of 5 to 50 mol ethylene oxide with 1 mol hardened castor oil as emulsifier enables suppositories containing aqueous active-principle solutions to be prepared. The emulsifier is preferably present in a quantity of 0.2 to 10% by weight. Suppositories containing up to 30% by weight water dispersed therein can be prepared using the above composition.

Abstract: Antioxidant compositions and methods are disclosed that are prepared by the extraction of natural antioxidants from plant substrates.

Abstract: Compositions and methods are disclosed for the treatment of obesity, depression, drug abuse, and narcolepsy. The compositions comprise a norepinephrine precursor such as L-tyrosine or L-phenylalanine in combination with a norepinephrine re-uptake inhibitor such as desipramine. In another embodiment of the invention, the compositions further comprise enzymatic cofactors for the biosynthesis of norepinephrine.

Abstract: A liposome composition designed for enhanced binding to mucosal tissue, The liposomes contain about 10-40 mole percent of an amine-derivatized lipid component in which a charged amine group is spaced from a lipid polar head region by a carbon-containing spacer arm at least 3 atoms in length. The liposomes preferably have a close packed lipid structure produced by inclusion of between 20-50 mole percent of cholesterol or an amine-derivatized cholesterol, and/or phospholipids with predominantly saturated acyl chain moieties. For ophthalmic use, the liposomes may be suspended in an aqueous medium containing a high-viscosity polymer, to enhance further the retention of liposomes on a corneal surface.

Abstract: A suppository base comprises 80 to 99 percent by weight of a lauric-type fat having a hydroxyl value of 20 or smaller and containing glycerides of fatty acids having 8 to 18 carbon atoms as the main component and 1 to 20 percent by weight of diglycerides of fatty acids having 14 to 22 carbon atoms and provides an improvement in the discharging property of a medicine contained therein.

Abstract: Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof.Also disclosed is the use of the 5.dbd.-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof for the same purpose.

Abstract: A liposome composition with enhanced retention on ocular surfaces, for use in ophthalmic drug delivery and dry eye treatment. The liposomes contain about 10-40 mole percent of an amine-derivatized lipid component in which a charged amine group is spaced from a lipid polar head region by a carbon-containing spacer arm at least 3 atoms in length. The liposomes preferably have a close packed lipid structure produced by inclusion of between 20-50 mole percent of cholesterol or an amine-derivatized cholesterol, and/or phospholipids with predominantly saturated acyl chain moieties. The liposomes may be suspended in an aqueous medium containing a high-viscosity polymer, formulated in paste form, or embedded in a polymer matrix, to enhance further the retention of liposomes on a corneal surface.

Abstract: The present invention relates to a new oral pharmaceutical composition having an improved release of the therapeutically active compound present therein, in the lower part of the gastro-intestinal duct having a pH exceeding 4.5, comprising as a core a therapeutically active compound in the form of a weak base, or a weak acid, on which core there is applied a first, inner layer of a diffusion membrane in the form of ethyl cellulose, and/or a copolymer of polyethyl methacrylate-methyl methacrylate-trimethylammonium ethyl methacrylate chloride, and thereabove a second layer is applied of at least one anionic polymer and/or fatty acid having a pk.sub.a of 4.5 to 7.The invention further relates to a process for the preparation of said composition, a pharmaceutical composition containing said composition, and a method for the treatment using such a composition.

Abstract: Biphenylylpropionic acid derivatives of the formula: ##STR1## wherein R is an alkylcarbonyloxyalkyl group or an alkenylcarbonyloxyalkyl group having the formula: ##STR2## wherein R.sup.1 is a lower alkyl group having 1 to 5 carbon atoms and R.sup.2 is an alkyl group having 1 to 15 carbon atoms or an alkenyl group having 2 to 8 carbon atoms, or a lactone having the formula: ##STR3## wherein R.sup.3 and R.sup.4 are hydrogen atom or a lower alkyl group having 1 to 2 carbon atoms, and n is an integer of 1 or 2. The compounds have excellent anti-inflammatory, analgesic and antipyretic activities. Moreover, the compounds have no irritation, rapid and long-acting, and high safety margin.

Abstract: The rectal absorption of the beta-lactam antibiotic ceftriaxone in a solid dosage form is enhanced with chenodeoxycholic acid or its sodium salt, in the presence of a carrier consisting of a mixture of two or more glycerides of C.sub.12 to C.sub.18 fatty acids.

Abstract: Iodophor-containing suppositories are provided with improved rate of iodine release from the suppository. The suppository composition comprises an iodophor, a water soluble suppository base, at least one water soluble sugar having a molecular weight of between about 90 and 550, and water in an amount of at least about 30% by weight. The molecular weight of the sugar is preferably between about 150 and 370. The preferred iodophors are providone iodine and polydextrose iodine. The preferred suppository bases are gelling polysaccharides and the preferred sugars are monosaccharides, disaccharides and sugar alcohols. The rate of iodine release is improved because of the high concentration of water together with the presence of the low molecular weight sugar.

Abstract: The invention relates to liquid, transparent, multicomponent systems for use in pharmaceutical products for cutaneous, peroral, vaginal and parenteral administration of pharmaceutical active agents. The multicomponent systems according to the invention contain the active agents in a solution of an oily and optionally an aqueous component in the presence of certain physiologically acceptable surfactants and cosurfactants. Under certain conditions, the cosurfactants can serve as oil components or the latter can optionally take over the cosurfactant function. The biological availability of the active agents applied in the form of the multicomponent systems according to the invention is much better than that of active agents applied in the form of known multicomponent systems.

Abstract: A controlled-release pharmaceutical unit dosage form is provided comprising a gelatin capsule enclosing a solid matrix formed by the cation-assisted gellation of a liquid fill incorporating a vegetable gum and a pharmaceutically-active compound, as well as methods for the preparation thereof.

Abstract: A rectally administered unit dosage form comprising a therapeutically effective amount of an analgesic , an antipyretic or an anti-inflammatory agent capable of being absorbed into the bloodstream from a rectal compartment and an adjuvant, said adjuvant comprising lecithin present in said dosage form in a sufficient amount to be effective in enhancing and prolonging the absorption rate of said analgesic, antipyretic or anti-inflammatory agent from the rectal compartment into the bloodstream, in conjunction with a nontoxic, pharmaceutically acceptable carrier and the methods of using said unit dosage form.

Abstract: A medicated suppository for use in the vaginal or rectal cavity comprising a medicament, a mixture of triglycerides of fatty acids, a gel forming agent and a gel dispersing agent is described.

Abstract: A solid sustained release dosage form is disclosed comprising a gel matrix containing HPMC and a major amount of a plasticizer therefor into which gel matrix is reversibly dispersed a pharmaceutically active agent.

Abstract: A hemorrhoidal remedy which comprises a salve consisting primarily of aluminum potassium sulfate, linseed oil, methanol, camphor and pure petroleum jelly. There is further provided a process for combining the aluminum potassium sulfate and mixing thoroughly with one ounce of linseed oil. Upon the aluminum sulfate and the linseed oil being thoroughly mixed, there is then added approximately one-half ounce of menthol, one quarter ounce of camphor to the mixture of the aluminum potassium sulfate and linseed oil. Following the thorough mixing of these ingredients, the pure petroleum jelly is added in and thoroughly mixed, utilizing approximately four ounces of the jelly.

Abstract: Antirheumatically active suppositories with comparable bioavailability to oral or parenteral preparations are described, which contain a salt of a compound of general Formula I ##STR1## in which R.sup.1 represents a heterocyclic ring and X together with Y an annelated aromatic ring; and an organic base of the general Formula IIR.sup.2 --NH--CH.sub.2 --(CHOH).sub.4 --CH.sub.2 OHin which R.sup.2 represents a hydrogen atom or an alkyl group with one to six carbon atoms, especially a methyl, ethyl, or propyl group; in a usual suppository base, are described.

Abstract: The invention relates to synergistic antiphlogistic pharmaceutical compositions comprising a pyrido [1,2-a]-pyrimidine derivative of the Formula I ##STR1## wherein R.sup.1 and R.sup.2 are lower alkyl and R.sup.3 stands for lower alkoxycarbonyl or carbamoyl and the dotted line represents an optionally hydrogenated band or a salt or quaternary salt thereof and 1-[p-chloro-benzoly]-2-methyl-5-methoxy-indolyl-3-acetic acid of the Formula II ##STR2## The advantage of the compositions is that as a result of the synergistic activity of the compound of the Formula I, the antiphlogistic Indomethacin of the Formula II can be administered in a significantly lower doses and consequently the unfavorable side effects of the latter compound are mitigated.

Abstract: An antitumor composition comprising a pharmacologically effective quantity of an ester of 1-.beta.-D-arabinofuranosylcytosine-5'-phosphate represented by the general formula ##STR1## where R is a monovalent aliphatic hydrocarbon group having 14 to 23 carbon atoms, and A designates a hydrogen atom or a pharmaceutically-acceptable alkali cation, and a vehicle is effective when administered by a non-injection method, particularly orally.